Marktanalyse - Osteoarthritis - Pipeline Review, H1 2017

Global Markets Direct
03.2017
270 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Osteoarthritis - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis — Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Osteoarthritis - Overview 11

Osteoarthritis - Therapeutics Development 12

Pipeline Overview 12

Pipeline by Companies 13

Pipeline by Universities/Institutes 19

Products under Development by Companies 20

Products under Development by Universities/Institutes 26

Osteoarthritis - Therapeutics Assessment 27

Assessment by Target 27

Assessment by Mechanism of Action 30

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Osteoarthritis - Companies Involved in Therapeutics Development 37

A. Menarini Industrie Farmaceutiche Riunite Srl 37

AbbVie Inc 37

Abiogen Pharma SpA 38

Ablynx NV 38

Achelios Therapeutics Inc 39

Addex Therapeutics Ltd 39

Amgen Inc 40

Amura Holdings Ltd 40

Arcarios BV 41

Asahi Kasei Pharma Corp 41

Asklepios BioPharmaceutical Inc 42

Astellas Pharma Inc 42

Biopharm GmbH 43

Bone Therapeutics SA 43

Can-Fite BioPharma Ltd 44

Cardax Inc 44

Cellular Biomedicine Group Inc 45

Cipla Ltd 45

Corestem Inc 46

Dong-A Socio Holdings Co Ltd 46

Evgen Pharma Plc 47

F. Hoffmann-La Roche Ltd 47

Galapagos NV 48

Gemphire Therapeutics Inc 48

GeneFrontier Corp 49

Genequine Biotherapeutics GmbH 49

GlaxoSmithKline Plc 50

HSRx Group 50

InKemia IUCT Group SA 51

International Stem Cell Corp 51

Jeil Pharmaceutical Co Ltd 52

Jenrin Discovery Inc 52

K-Stemcell Co Ltd 53

Kang Stem Biotech Co Ltd 53

Levolta Pharmaceuticals Inc 54

LG Chem, Ltd. 54

Marina Biotech Inc 55

Medivir AB 55

Merck KGaA 56

Mesoblast Ltd 56

Mor Research Application Ltd 57

NicOx SA 57

Nordic Bioscience A/S 58

Novartis AG 58

NovelMed Therapeutics Inc 59

Omeros Corp 59

Ono Pharmaceutical Co Ltd 60

OrthoCyte Corp 60

Osteologix Holdings Plc 61

Pfizer Inc 61

Pharmalink AB 62

Philogen SpA 62

PhytoHealth Corp 63

PLx Pharma Inc 63

ProteoThera Inc 64

Regeneus Ltd 64

Regulaxis SAS 65

Rottapharm Biotech Srl 65

Samumed LLC 66

Seikagaku Corp 66

Stelis Biopharma Pvt Ltd 67

Takeda Pharmaceutical Company Ltd 67

TissueGene Inc 68

Yooyoung Pharmaceutical Co Ltd 68

Yuhan Corp 69

Yungjin Pharm Co Ltd 69

Zimmer Biomet Holdings Inc 70

Osteoarthritis - Drug Profiles 71

(clodronate disodium + hyaluronic acid) - Drug Profile 71

(methylprednisolone + zoledronic acid) - Drug Profile 72

4-P004 - Drug Profile 74

ABT-981 - Drug Profile 75

ALLO-ASC - Drug Profile 76

AlloJoin - Drug Profile 78

AM-3701 - Drug Profile 79

AM-3876 - Drug Profile 80

Anatabine - Drug Profile 81

Antibody for Osteoarthritis - Drug Profile 84

Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 85

apocynin + paeonol - Drug Profile 86

ARC-118 - Drug Profile 87

AS-001 - Drug Profile 88

BNP-OA - Drug Profile 89

CDX-085 - Drug Profile 90

celecoxib - Drug Profile 93

Cell Therapy for Osteoarthritis - Drug Profile 94

Chondrostem - Drug Profile 95

clodronate disodium - Drug Profile 96

CMX-020 - Drug Profile 97

CR-8357 - Drug Profile 98

CRB-0017 - Drug Profile 99

CS-30MS02 - Drug Profile 100

DA-5202 - Drug Profile 101

denosumab - Drug Profile 102

DIS-BIO-EPS - Drug Profile 112

DNX-314 - Drug Profile 113

Drug for Bone Diseases and Osteoarthritis - Drug Profile 114

Drug for Osteoarthritis - Drug Profile 115

Drug for Osteoarthritis - Drug Profile 116

Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 117

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 118

fasitibant chloride - Drug Profile 119

gemcabene calcium - Drug Profile 120

GFC-301 - Drug Profile 124

GLPG-1972 - Drug Profile 125

GQ-203 - Drug Profile 126

GQ-303 - Drug Profile 127

GSK-2394002 - Drug Profile 128

JD-4000 Series - Drug Profile 129

Jointstem - Drug Profile 130

JTA-004 - Drug Profile 132

Kartogenin - Drug Profile 133

KBP-056 - Drug Profile 134

ketoprofen - Drug Profile 135

LEVI-04 - Drug Profile 137

LH-021 - Drug Profile 138

LNA-043 - Drug Profile 139

MIV-711 - Drug Profile 140

Monoclonal Antibodies for Oncology, Inflammation and Osteoarthritis - Drug Profile 143

Monoclonal Antibody Conjugates for Osteoarthritis - Drug Profile 144

Monoclonal Antibody for Osteoarthritis - Drug Profile 145

MPC-75IA - Drug Profile 146

naproxcinod - Drug Profile 147

NBS-101 - Drug Profile 150

NStride APS - Drug Profile 152

ONO-4474 - Drug Profile 153

OTXCP-03 - Drug Profile 154

OTXCP-07 - Drug Profile 155

PF-152 - Drug Profile 156

PHDC-02 - Drug Profile 157

piclidenoson - Drug Profile 158

PL-1100 - Drug Profile 167

PN-6047 - Drug Profile 168

PRO-1 - Drug Profile 169

Progenza - Drug Profile 170

Protein for Osteoarthritis and Asthma - Drug Profile 172

Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile 173

PRX-167700 - Drug Profile 174

Recombinant Protein for Osteoarthritis - Drug Profile 176

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 177

Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 179

Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile 180

Reg-O3 - Drug Profile 181

ReJoin - Drug Profile 182

salmon calcitonin - Drug Profile 186

SBL-005 - Drug Profile 188

SFX-01 - Drug Profile 189

SI-613 - Drug Profile 192

SM-04690 - Drug Profile 193

Small Molecule for Degenerative Arthritis - Drug Profile 196

Small Molecule for Osteoarthritis - Drug Profile 197

Small Molecule for Osteoarthritis - Drug Profile 198

Small Molecule for Osteoarthritis - Drug Profile 199

Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 200

Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 201

Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 202

Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 203

Small Molecules for Osteoarthritis - Drug Profile 204

Small Molecules for Osteoarthritis - Drug Profile 205

Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile 206

Small Molecules to Inhibit iNOS for Osteoarthritis - Drug Profile 207

Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 208

sprifermin - Drug Profile 209

Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis - Drug Profile 211

Stem Cell Therapy for Autoimmune Diseases - Drug Profile 212

Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 214

Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile 215

Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis - Drug Profile 216

Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans - Drug Profile 217

Stempeucel - Drug Profile 218

tonogenchoncel-L - Drug Profile 221

TPX-100 - Drug Profile 224

TRBN-0224 - Drug Profile 226

UGP-302 - Drug Profile 228

VA-694 - Drug Profile 230

X-0002 - Drug Profile 231

XT-101 - Drug Profile 233

XT-150 - Drug Profile 234

YH-14619 - Drug Profile 235

YRA-1909 - Drug Profile 236

YY-1201 - Drug Profile 237

YYD-302 - Drug Profile 238

Osteoarthritis - Dormant Projects 239

Osteoarthritis - Discontinued Products 246

Osteoarthritis - Product Development Milestones 248

Featured News & Press Releases 248

Appendix 261

Methodology 261

Coverage 261

Secondary Research 261

Primary Research 261

Expert Panel Validation 261

Contact Us 261

Disclaimer 262





List of Tables

Number of Products under Development for Osteoarthritis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017

Osteoarthritis - Pipeline by AbbVie Inc, H1 2017

Osteoarthritis - Pipeline by Abiogen Pharma SpA, H1 2017

Osteoarthritis - Pipeline by Ablynx NV, H1 2017

Osteoarthritis - Pipeline by Achelios Therapeutics Inc, H1 2017

Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2017

Osteoarthritis - Pipeline by Amgen Inc, H1 2017

Osteoarthritis - Pipeline by Amura Holdings Ltd, H1 2017

Osteoarthritis - Pipeline by Arcarios BV, H1 2017

Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2017

Osteoarthritis - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017

Osteoarthritis - Pipeline by Astellas Pharma Inc, H1 2017

Osteoarthritis - Pipeline by Biopharm GmbH, H1 2017

Osteoarthritis - Pipeline by Bone Therapeutics SA, H1 2017

Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2017

Osteoarthritis - Pipeline by Cardax Inc, H1 2017

Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, H1 2017

Osteoarthritis - Pipeline by Cipla Ltd, H1 2017

Osteoarthritis - Pipeline by Corestem Inc, H1 2017

Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Osteoarthritis - Pipeline by Evgen Pharma Plc, H1 2017

Osteoarthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Osteoarthritis - Pipeline by Galapagos NV, H1 2017

Osteoarthritis - Pipeline by Gemphire Therapeutics Inc, H1 2017

Osteoarthritis - Pipeline by GeneFrontier Corp, H1 2017

Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2017

Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2017

Osteoarthritis - Pipeline by HSRx Group, H1 2017

Osteoarthritis - Pipeline by InKemia IUCT Group SA, H1 2017

Osteoarthritis - Pipeline by International Stem Cell Corp, H1 2017

Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Osteoarthritis - Pipeline by Jenrin Discovery Inc, H1 2017

Osteoarthritis - Pipeline by K-Stemcell Co Ltd, H1 2017

Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017

Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, H1 2017

Osteoarthritis - Pipeline by LG Chem, Ltd., H1 2017

Osteoarthritis - Pipeline by Marina Biotech Inc, H1 2017

Osteoarthritis - Pipeline by Medivir AB, H1 2017

Osteoarthritis - Pipeline by Merck KGaA, H1 2017

Osteoarthritis - Pipeline by Mesoblast Ltd, H1 2017

Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2017

Osteoarthritis - Pipeline by NicOx SA, H1 2017

Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2017

Osteoarthritis - Pipeline by Novartis AG, H1 2017

Osteoarthritis - Pipeline by NovelMed Therapeutics Inc, H1 2017

Osteoarthritis - Pipeline by Omeros Corp, H1 2017

Osteoarthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Osteoarthritis - Pipeline by OrthoCyte Corp, H1 2017

Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2017

Osteoarthritis - Pipeline by Pfizer Inc, H1 2017

Osteoarthritis - Pipeline by Pharmalink AB, H1 2017

Osteoarthritis - Pipeline by Philogen SpA, H1 2017

Osteoarthritis - Pipeline by PhytoHealth Corp, H1 2017

Osteoarthritis - Pipeline by PLx Pharma Inc, H1 2017

Osteoarthritis - Pipeline by ProteoThera Inc, H1 2017

Osteoarthritis - Pipeline by Regeneus Ltd, H1 2017

Osteoarthritis - Pipeline by Regulaxis SAS, H1 2017

Osteoarthritis - Pipeline by Rottapharm Biotech Srl, H1 2017

Osteoarthritis - Pipeline by Samumed LLC, H1 2017

Osteoarthritis - Pipeline by Seikagaku Corp, H1 2017

Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017

Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Osteoarthritis - Pipeline by TissueGene Inc, H1 2017

Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017

Osteoarthritis - Pipeline by Yuhan Corp, H1 2017

Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2017

Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H1 2017

Osteoarthritis - Dormant Projects, H1 2017

Osteoarthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017

Osteoarthritis - Dormant Projects, H1 2017 (Contd..2), H1 2017

Osteoarthritis - Dormant Projects, H1 2017 (Contd..3), H1 2017

Osteoarthritis - Dormant Projects, H1 2017 (Contd..4), H1 2017

Osteoarthritis - Dormant Projects, H1 2017 (Contd..5), H1 2017

Osteoarthritis - Discontinued Products, H1 2017

Osteoarthritis - Discontinued Products, H1 2017 (Contd..1), H1 2017





List of Figures

Number of Products under Development for Osteoarthritis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus